THE GAP
For fifty years, researchers and attorneys advanced plant medicine science and policy without institutional recognition. They published groundbreaking findings when grant committees blacklisted cannabis. They litigated medical necessity when courts treated it as criminal defense. They built clinical evidence bases while risking tenure, funding, and professional standing. No hall of fame existed to recognize them. No formal record acknowledged their contributions. No credential validated the professional risk they took. Many are still working. Some have passed. All of them built the field that federal rescheduling now validates. This is the recognition they should have received decades ago.
EXAMPLES OF PIONEER CONTRIBUTIONS
If this existed in 1988, we would have inducted DEA Administrative Law Judge Francis Young, who concluded cannabis is "one of the safest therapeutically active substances known to man" and recommended rescheduling — only to have the DEA reject his findings. If this existed in 1992, we would have inducted the attorneys who fought to keep the IND program open when the federal government closed the only legal pathway to medical cannabis, cutting off hundreds of AIDS patients mid-application. If this existed in 1999, we would have inducted the Institute of Medicine researchers whose landmark report documented cannabis efficacy despite federal resistance to the findings. If this existed in 2003, we would have inducted Tod Mikuriya, MD, who maintained the largest private practice database of cannabis patients in the country while facing medical board persecution for his work. If this existed in 2010, we would have inducted Raphael Mechoulam, whose discovery of the endocannabinoid system opened an entire field of biomedical science — work conducted in Israel because U.S. institutions wouldn't fund it. These contributions happened. The recognition didn't.
WHAT MAKES SOMEONE HALL OF FAME WORTHY
RESEARCH TRACK (Cannabis or Psychedelics) Scientific contributions that advanced therapeutic understanding, clinical practice, or mechanistic knowledge: Peer-reviewed publications that opened new areas of investigation or contradicted federal narratives with rigorous evidence Clinical trials or observational studies that influenced patient care protocols or safety standards Discovery work on biological mechanisms, receptor systems, or therapeutic pathways Methodological innovation that enabled subsequent research by others Sustained contribution over time despite funding barriers, institutional resistance, or career risk LEGAL/POLICY TRACK (Cannabis or Psychedelics) Legal or advocacy work that advanced patient access, research protections, or policy reform: Litigation establishing medical necessity, patient rights, or constitutional protections for medical use Legislative drafting or advocacy resulting in state or federal policy change Legal strategy underlying rescheduling petitions, regulatory reform, or research pathway expansion Defense work protecting researchers, clinicians, or patients facing prosecution for plant medicine work Civil rights litigation expanding access or challenging discriminatory enforcement
WHY RECOGNITION CREATES LEVERAGE
Hall of Fame induction isn't symbolic. It's structural. Grant applications: "Hall of Fame Inductee" signals peer-evaluated excellence to review committees Tenure and promotion: Formalizes contributions that institutional committees may not understand or value Expert witness qualification: Establishes credibility in proceedings where cannabis/psychedelics expertise is challenged Career validation: Confirms that plant medicine work is scientifically legitimate and professionally viable Funding credibility: Demonstrates the field has rigorous standards and recognized leaders Historical record: Prevents erasure of contributions made when institutions refused to acknowledge them An inductee writes "Hall of Fame Honoree" on every CV, grant application, and expert qualification for the rest of their career.
0+
Pioneering researchers honored
100+
Peer-reviewed publications advanced
1000+
Clinical trials conducted and supported
4
Major therapeutic fields transformed
SELECTION PROCESS
Independent expert panel evaluates nominees under blind review protocols. Panel members have no affiliation with Patients Out of Time and receive no compensation. Selection criteria: Scientific or legal contribution to the field Professional courage under institutional resistance Sustained impact on research, policy, or patient access Evidence of work conducted despite barriers Nomination volume does not influence Expert Panel selection. The People's Choice Award is determined separately by community support.